Chief Executive Officer
Tue, Apr 18, 2023
Apr 18
exercised or converted securities in APLS
30,000 shares @ $0.00
Decreased holdings by -7.50%
Net across this filing: +3.10% (+20,000 shares)
Option Exercise
Sale tied to a same-time option exercise
Win rate excludes trades classified as routine (tax, 10b5-1, exercise, gift).
APLSApellis Pharmaceuticals, Inc.
HealthcareBiotechnology